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Abstract
In a number of countries, whole cell pertussis vaccines (wcP) were replaced by acellular vaccines (aP) due to an improved
reactogenicity profile. Pertussis immunization leads to specific antibody production with the help of CD4
+ T cells. In earlier
studies in infants and young children, wcP vaccines selectively induced a Th1 dominated immune response, whereas aP
vaccines led to a Th2 biased response. To obtain data on Th1 or Th2 dominance of the immune response in adolescents
receiving an aP booster immunization after a wcP or aP primary immunization, we analyzed the concentration of Th1 (IL-2,
TNF-a, INF-c) and Th2 (IL-4, IL-5, IL-10) cytokines in supernatants of lymphocyte cultures specifically stimulated with
pertussis antigens. We also investigated the presence of cytotoxic T cell responses against the facultative intracellular
bacterium Bordetella pertussis by quantifying pertussis-specific CD8
+ T cell activation following the aP booster
immunization. Here we show that the adolescent aP booster vaccination predominantly leads to a Th1 immune response
based on IFNgamma secretion upon stimulation with pertussis antigen, irrespective of a prior whole cell or acellular primary
vaccination. The vaccination also induces an increase in peripheral CD8
+CD69
+ activated pertussis-specific memory T cells
four weeks after vaccination. The Th1 bias of this immune response could play a role for the decreased local reactogenicity
of this adolescent aP booster immunization when compared to the preceding childhood acellular pertussis booster.
Pertussis-specific CD8
+ memory T cells may contribute to protection against clinical pertussis.
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Introduction
Bordetella pertussis is a facultative intracellular bacterium
associated with respiratory tract infections which may become
life threatening especially in infants. In 2003, the WHO reported
an estimated 17.6 million cases worldwide, resulting in 279.000
pertussis related deaths [1]. Young adults are the main source for
transmission of pertussis to young unvaccinated infants [2–4]. For
this reason, pertussis booster vaccinations for all adolescents, for all
adults, or for adults with close contact to infants, are recom-
mended in a number of countries, including the USA, Germany,
France and Italy.
For many years only whole cell pertussis vaccines (wcP) were
available. However, a considerable rate of systemic adverse effects
were associated with their use [5]. Therefore, in a number of
countries, wcP vaccines were replaced by acellular vaccines (aP) in
the mid 1990s because of their improved reactogenicity profile [5].
The immune response induced by wcP and aP vaccines is
different: wcP vaccines, like natural pertussis infections, selectively
induce Th1 cells, characterized by a cytokine pattern consisting
mainly of IL-2, TNF-a, and INF-c; aP vaccines lead to a Th2-
polarized cytokine pattern (mainly IL-4, IL-5) in infants and
children at 4-6 years of age [6-9]. Importantly, when investigating
long-term immune responses, these different effects may be
masked by subclinical pertussis infections, which act as silent,
natural boosters. In aP-vaccinated children, these silent boosters
may cause a switch to the Th1 predominant phenotype [10].
We have recently shown that adolescents receiving an aP booster
immunization are able to initiate substantial lymphoproliferative,
cell mediated immunity (CMI) to pertussis antigens, not only when
the initial immunization was wcP, but also with an exclusively
acellular vaccination regimen [11]. In this study, we determined
whether the distinct T helper cell responses normally seen following
wcPversus aPpreimmunization stillexists afterthe delivery ofan aP
booster immunization inadolescents. Presumingan additive role for
a cytotoxic T cell response against the facultative intracellular
bacterium B. pertussis we also investigated pertussis-specific CD8
+ T
cell activation following vaccination with an aP booster.
Our study population consisted of three groups of adolescents
who had received either 4 wcP, 4aP or 5aP doses during infancy
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17271and early childhood. The participants with 5 aP doses belong to
the first cohort of adolescents to have received 5 consecutive aP
vaccinations in childhood before their adolescent aP booster
vaccination. This schedule is now generally recommended in
several countries, including the USA, France and Germany.
Materials and Methods
Ethics statement
The study protocol was approved by the local ethical review
board of the University of Munich, Germany, and by the Paul-
Ehrlich-Institute, Langen, Germany. The study was conducted
according to Good Clinical Practice and in accordance with the
Declaration of Helsinki. Written, informed assent from each
participant and written, informed consent from the parent/legal
guardian was obtained prior to study entry.
Study population
Thisopenmulticenterstudy wascarried out to examine pertussis-
specific T cell immune responses before and after aP booster
vaccination in adolescents with different childhood pertussis
vaccination schedules. Patients were recruited from pediatric
practices in Germany and in the outpatient department of the
University Children’s Hospital, Ludwig-Maximilians-University,
Munich.
A clinical trial examiningreactogenicity and immunogenicity of a
Tdap or Tdap plus polio vaccination given as the 6
th consecutive
acellular pertussis dose in 10-14 year old adolescents in Germany
was conducted in parallel with the present study [11,12]. Study
investigators of the clinical trial were asked to participate as
investigators in this study. Adolescents 10–14 years of age with no
obvious health problems and no immunosuppressive treatment
were enrolled, provided they had previously received either 5 doses
of an acellular pertussis vaccine (Biken DTaP, last dose age 4 to 6
years) [13,14] (5aP group), 4 doses of an acellular pertussis vaccine
(Biken DTaP, last dose age 18 to 24 months) [13] (4aP group), or 4
doses of a whole-cell pertussis vaccine (DPT-ImpfstoffH, Behring-
werke, Marburg, Germany, last dose age 18 to 24 months) (4wcP
group). The Biken DTaP was a sterile preparation of a two
component acellular pertussis vaccine with pertussis toxin (PT)
and filamentous hemagglutinin (FHA) manufactured by Biken and
Tanabe Corp. (Osaka, Japan) combined with adsorbed diphtheria
and tetanus toxoids by Aventis Pasteur Inc. (Swiftwater, PA). Each
0.5-ml dose contained 6.7 limes flocculation units (Lf) of diphtheria
toxoid, 5.0 Lf of tetanus toxoid, 23.4 mg of detoxified PT and
23.4 mg of detoxified FHA, thimerosal 1/10 000 (25 mg), sodium
phosphate and sodium chloride. The whole-cell pertussis vaccine
DPT-ImpfstoffH consisted of 4 IU of B. pertussis, 30 IU of diphtheria
toxoid, 40 IU of tetanus toxoid and 0.75 mg of aluminum
hydroxide/aluminum phosphate and was used as comparative
whole-cell vaccine in an acellular pertussis vaccine efficacy study in
Germany [13]. At the time of the study, an adolescent booster
vaccination against pertussis, diphtheria and tetanus was recom-
mended in Germany for all participants. No participants with a
history of clinical pertussis disease were enrolled in the study.
Study vaccine
Only licensed products provided by Sanofi Pasteur MSD,
Leimen, Germany were used. Participants received either REPE-
VAXH, COVAXISH, or COVAXISH and IPV MERIEUXH.
COVAXISH contains in each 0.5-ml dose 2.5 mg pertussis
toxoid (PT), 5 mg filamentous hemagglutinin (FHA), 3 mg pertactin
(PRN), 5 mg fimbriae types 2 and 3 (FIM), 2 Lf diphtheria toxoid,
5 Lf tetanus toxoid, 1.5 mg aluminum phosphate and 0.6% 2-
phenoxyethanol. COVAXISH and IPV-MerieuxH are identical to
the US-licensed products ADACELH and IPOLH, respectively.
REPEVAXH, the combination of the two, is not marketed in
North America.
In addition to the same acellular pertussis antigens and content,
each 0.5-ml dose of REPEVAXH additionally contains inactivated,
Vero cell-derived poliomyelitis vaccine (vero cell origin) (Poliovirus
Type 1: 40 D units, Poliovirus Type 2: 8 D units, Poliovirus Type
3: 32 D units).
IPV MERIEUXH contains in each 0.5-ml dose inactivated,
Vero cell-derived poliomyelitis vaccine (vero cell origin) (Poliovirus
Type 1: 40 D units, Poliovirus Type 2: 8 D units, Poliovirus Type
3: 32 D units).
Study procedures
Participants of the 5aP group and the 4wcP group received 1 dose
of REPEVAX vaccine in the left arm, or 1 dose of COVAXIS
vaccine in the left arm plus 1 optional dose of IPV MERIEUX
vaccine in the right arm, as determined by their randomisation in
the parallel clinical reactogenicity trial [12].
4aP group participants received 1 dose of REPEVAX vaccine in
the left arm, or 1 dose of COVAXIS vaccine in the left arm plus
one optional dose of IPV MERIEUX vaccine in the right arm as
recommended by their physician.
From every participant, a 10-ml heparinized blood sample (20 IU
heparin per ml) and a 3-ml serum sample were drawn directly before
vaccination and 28–36 days after vaccination. The blood samples
were sent at room temperature to the Laboratory of Immunology at
the University Children’s Hospital, Ludwig-Maximilians-University,
Munich, Germany and were processed within 24 hours.
Preparation of peripheral blood mononuclear cells
(PBMC)
PBMC were prepared by Ficoll density gradient sedimentation
(Lymphocyte Separation Medium, Biochrom, Berlin, Germany)
and washed twice in RPMI 1640 (Biochrom, Berlin, Germany).
Trypan blue staining solution at 0.5% differentiated between
viable and nonviable cells. Only samples with vitality of .80%
were evaluated. PBMC were resuspended at 1.5610
6 cells/ml in
RPMI 1640 supplemented with 5% heat-inactivated (30 min at
56uC) human serum and 1% penicillin (Biochrom, Berlin,
Germany), hereafter referred to as complete medium.
Lymphocyte stimulation
PBMC (1.5610
5) were cultured in round-bottom microtitre
plates (Greiner bio-one, Frickenhausen, Germany) in 100 ml
complete medium per well in the presence of one of the following
antigens: PT/FHA/PRN/FIM 2/3 (all provided by Sanofi
Pasteur Inc., Swiftwater, PA, USA) or tetanus- plus diphtheria-
toxoid (DT) (Chiron Behring GmbH, Liederbach, Germany). The
following optimized antigen concentrations were added [6]: PT
2 mg/ml (heat-inactivated at 80uC for 20 min), FHA 10 mg/ml,
PRN 10 mg/ml, FIM 2/3 10 mg/ml, and DT 7.22 Lf/ml each.
Cultures containing medium without antigens were negative
controls. Because of limited numbers of PBMC available, not all
of the individuals were tested for each antigen. Cell cultures were
performed in a humidified atmosphere at 37uC and 5% CO2.
Immunophenotyping
Immunophenotyping of peripheral blood lymphocytes was
performed using anti-human monoclonal antibodies (FITC anti-
human CD69, PE-Cy5 anti-human CD4, APC anti-human CD8,
all BD Biosciences Pharmingen
TM, San Jose, USA).
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incubated for 30 min in the dark with 3 ml of each antibody in
FACS tubes (5 ml round-bottom tubes, BD Falcon). The cells were
washed with 2.5 ml PBS (phosphate buffered saline, Dulbecco 1*,
LE, Biochrom AG) and analyzed on a FACSCalibur flow
cytometer (Becton Dickinson, NJ, USA) with data stored in list
mode files. Ten thousand cells were analyzed for each sample.
Isotype- and fluorochrome- matched control MAb were used to
determine nonspecific background binding.
Cytokine measurement
To determine pertussis-specific cytokine production, 90 mlo f
supernatant of lymphocyte stimulation cultures were harvested
after 48 hours, quick-frozen and stored at 220uC. The ‘‘Human
Th1/Th2 cytometric bead array-Kit’’ (BD Biosciences, San Jose,
USA) was used for the analysis according to manufacturer’s
instructions. Results were obtained with BD CBA Biosciences
software (BD Biosciences, San Jose, USA). Cytokine quantification
was performed for representative Th1 (IL-2, TNF-a, INF-c) and
Th2 (IL-4, IL-5, IL-10) cytokines.
Data analysis and statistical methods
Data were analyzed with GraphPad Prism version 4.01 for
Windows (GraphPad Software, San Diego, California, USA).
Wilcoxon matched-pair signed-rank test for non-parametric data
was used for analysis of pre- versus post-vaccination values for
Figure 1. CD69
+ antigen specific T cells after aP booster vaccination. Surface markers on T-lymphocytes were measured after 48 h of
stimulation with pertussis antigens (PT, FHA, PRN, FIM), without antigen stimulation (CO), or with diphtheria/tetanus (DT) antigen stimulation.
Immunophenotyping was performed prior to (pre) and 28–36 days after (post) aP booster vaccination. The percentages of CD8
+CD69
+ (a) and
CD4
+CD69
+ (b) lymphocytes within the total lymphocyte population are shown for all participants. To show outliers, the y-axis was divided into two
scales (tilde). Scatter blot; horizontal lines indicate the median value. * significant increase/decrease after vaccination (Wilcoxon-test; p,0.05).
** highly significant increase/decrease after vaccination (Wilcoxon-test; p,0.01).
doi:10.1371/journal.pone.0017271.g001
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a Mann-Whitney U Test for non-parametric data was performed.
For all analyses, a two-tailed P-value #0.05 was considered to be
significant.
Results
Demographic characteristics of participants
The study participants (n=78; 5aP group =37; 4aP group
=23; 4wcP group =18) were comprised of 33 girls and 45 boys.
The mean age of study participants was 12.4 years (age range
10.0–14.0 years). There were no substantial gender or age
differences between the three groups.
Immunophenotyping of lymphocyte activation
Immunophenotyping of lymphocyte differentiation and activa-
tion markers was performed with antibodies against CD4, CD8,
and CD69 in the antigen-stimulated cultures before and 4 weeks
after vaccination.
CD8
+CD69
+ cells in antigen stimulated cultures were more
frequent after vaccination than before (figure 1). This increase
after vaccination was significant for stimulation with all four tested
pertussis antigens (Wilcoxon test; PT: median increased from
0.67% to 1.14%, P,0.0001; FHA: median increased from 0.88%
to 1.35%, P=0.0209; PRN: median increased from 0.76% to
1.17%, P=0.0003; FIM: median increased from 0.88% to 1.07%,
P=0.0054). CD8
+CD69
+ activated lymphocytes increased in all
three groups independent of the different primary vaccination
schedules. Proportions of CD8
+CD69
+ cells did not change
significantly in DT stimulated or unstimulated control cultures.
CD4
+CD69
+ activated lymphocytes did not change after
vaccination in PT stimulated cultures and decreased in FHA
(median decreased from 0.70% to 0.48%, P=0.0141), in PRN
(median decreased from 0.82% to 0.54%, P=0.0195) and FIM
(median decreased from 0.77% to 0.57%, P=0.019) stimulated
cultures. There was again no significant change in DT stimulated
or unstimulated control cultures (figure 1).
Cytokine response
Cytokines indicative of a Th1 response (IL-2, TNF-a, INF-c)
and Th2 response (IL-4, IL-5, IL-10) were determined in
supernatants of PT-stimulated cultures after vaccination. From
these cytokines only INF-c and TNF-a were above the level of
detection (20 pg/ml) in a sufficient number of participants (49/78
(63%) and 29/78 (37%), respectively) to allow valid statistical
evaluation between the three groups. Scatter blots of the individual
INF-c and TNF-a values upon PT-stimulation in the three groups
are shown in figure 2. There were no significant differences
between the three groups in the INF-c and TNF-a secretion upon
PT-Stimulation (Mann-Whitney U test).
A Th2 cytokine secretion (IL-4, IL-5, IL-10) was seen in 11/78
(14%) participants. Table 1 summarizes the distribution between
the three groups. There were no detectable Th2 cytokine
responses in participants with exclusive wcP preimmunization.
Th2 response and reactogenicity to vaccination
A Th2 response to DTaP vaccination has been associated with
large local reactions such as extensive swelling of the whole limb
[15]. Information on the reactogenicity after vaccination exists for
nine of the eleven subjects with measurable Th2 cytokine secretion
(simultaneous participation in the reactogenicity study [12]). One
of these nine vaccinees showed large swelling and erythema,
whereas the remaining eight did not develop any swelling or
erythema. Taken together, the results of the nine vaccinees did not
show an apparently stronger reactogenicity (fever, pain, erythema,
swelling) than the general study population [12].
Discussion
Our study focused on the CD4
+ helper cell and CD8
+ cytotoxic
cell response in adolescents receiving an aP booster immunization
after whole cell or acellular primary vaccination. Here we show
that the adolescent aP booster vaccination in our study population
predominantly leads to a Th1 immune response, irrespective of a
whole cell or acellular primary vaccination. The vaccination also
induced a significant increase in CD8
+CD69
+ T cells responsive to
pertussis antigens. This study is the first to demonstrate CD8
+
memory T cell immune responses to pertussis vaccine.
Four weeks after the adolescent aP vaccination CD8
+CD69
+
activated T cells were augmented when PBMC were stimulated
with all four tested pertussis antigens, whereas CD4
+CD69
+ T cells
were decreased in FHA, PRN and FIM stimulated cultures. There
were no changes of proportions of CD8
+CD69
+ T cells or
Figure 2. IFN-c and TNF-a secretion after aP booster vaccina-
tion. Cytokine secretion in post-booster culture supernatants was
measured after 48 h of stimulation with PT by cytometric bead arrays.
To show outliers the y-axis was divided into two scales (tilde).
Horizontal lines indicate the median value.
doi:10.1371/journal.pone.0017271.g002
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+CD69
+ T cells in control cultures. These results suggest a
targeted activation of pertussis specific CD8
+ T cells after
vaccination. As expected for the quantification of antigen specific
T cells in peripheral blood, the percentage of T cells specifically
activated by pertussis antigens was generally low. A similar
percentage has recently also been shown for proliferating CD3
+
blasts in PT stimulated PBMC cultures after primary wcP
vaccination [16].
Priming of memory CD8
+ T cells has been described for
immunizations against several intracellular pathogens, particularly
viruses (e.g. encephalomyocarditis virus (EMCV), lymphocytic
choriomeningitis virus (LCMV), varizella zoster virus (VZV),
hepatitis B virus (HBV)) [17–23]. Memory CD8
+ T cells become
more rapidly induced to express activation markers or cytokine
receptors and to secrete higher levels of cytokines such as IFN-
gamma and IL-2 than naı ¨ve T cells. Such differences in immune
responses between naı ¨ve and memory CD8
+ T cells after
vaccination have already been described for the expression of
CD69 and IL2-receptor alpha chain (CD25) in humans [17,18,21]
and the secretion of IL-2 and INF-gamma in mice [19,20]. These
differences may lead to lower activation thresholds in primed
memory CD8
+ T cells compared to naı ¨ve CD8
+ T cells and might
play an important role in the cellular memory response after
vaccination, especially against facultative intracellular pathogens
like B. pertussis [24]. Such an important role for cytotoxic T cells
could at least partially explain why a protective antibody titer
against pertussis infection cannot be defined [25]. In mice,
however, clearance of B. pertussis from the lungs was mediated by
pertussis specific CD4
+, but not by CD8
+ T cells [26]. The role for
cytotoxic memory CD8
+ T cells in protecting humans from
clinical pertussis cannot be determined by our study.
Regarding cytokine secretion, we have shown here that the
adolescent aP booster vaccination predominantly leads to a Th1
immune response, irrespective of a previous whole cell or acellular
primary vaccination. Th1 predominant immune responses have
been observed after natural pertussis infections and wcP
vaccinations, whereas Th2-skewed immune responses were seen
after acellular pertussis vaccinations [6–9]. These results were
based on studies in infants and young children after their primary
aP vaccination. Among adolescents and adults from the APERT
study with either previous wcP or without previous pertussis
vaccination an aP dose led to a predominant Th1 response [27].
In our study only a few participants of the aP preimmunization
groups showed a Th2 cytokine secretion in vitro. In the vast
majority the adolescent aP booster primed T cells to a Th1
response even in the aP preimmunization groups. It can be
speculated that this might indicate previous exposure to B. pertussis
without development of typical symptoms, so called ‘silent’
boosting. Ausiello et al. have already demonstrated the switch
from a predominant Th2 immune response after acellular primary
vaccination in the first year of life to a predominant Th1 immune
response in 4 year old children before booster vaccination [10].
The most probable explanation to this phenomenon in this
longitudinal observation was natural exposure to B. pertussis and a
high rate of subclinical natural boosters. Studies on antibody
seroprevalence and cell-mediated immunity (CMI) in our
adolescent vaccinees also pointed to an influence of subclinical
natural boosters on pertussis specific immunity [11]. This
hypothesis is in line with data from Yano et al., who describe
that in adults who were once primed for a Th1-biased immune
response by wcP vaccine or by natural pertussis infection, the
pertussis specific T cell pool maintains their Th1-biased responses
even when boosted with aP vaccine [28].
A vigorous Th2 response after acellular pertussis vaccination in
infancy and early childhood is associated with large local reactions
like extensive swelling of the whole limb [15]. In our study, of 9
adolescents with measurable Th2 responses and available
reactogenicity data [12] one had a large local reaction. With
respect to the overall low number of participants with Th2
responses this does not clearly argue for or against that association.
Our 10–14 year old study population showed a markedly lower
rate of local reactions (swelling and redness at the injection site),
especially of large local reactions (redness/swelling .10 cm) [12],
than at the 4–6 year booster vaccination [14]. This decrease in
local reactogenicity within the two studies might primarily be due
to the use of an antigen-reduced acellular pertussis vaccine in
adolescents. A switch to a predominant Th1 response after
subclinical natural booster infections in the meantime could play
an additional role for the lower local reactogenicity.
In summary, this study shows that the adolescent aP booster
vaccination leads to a Th1 and CD8
+ memory T cell immune
response, which may contribute to a positive safety and efficacy
profile.
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Table 1. Distribution of participants and of Th1/Th2 cytokine secretion.
Group
Number of
participants
One or more Th1 cytokine(s)
above detection level
(IL-2, TNF-a,I N F - c)
One or more Th2 cytokine(s)
above detection level
(IL-4, IL-5, IL-10)
5aP group 37 28 (76%) 9 (24%)
4aP group 23 15 (65%) 2 (9%)
4wcP group 18 16 (89%) 0 (0%)
The distribution of all participants and of the participants with detectable Th1/Th2 cytokine secretion within the three vaccination groups is shown. There was no Th2
cytokine secretion detectable in participants with exclusive wcP preimmunization.
doi:10.1371/journal.pone.0017271.t001
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